CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome
- 25 November 2015
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 67 (12) , 3226-3233
Abstract
Objective: Non‐Hodgkin's lymphoma (NHL) is a severe complication of primary Sjögren's syndrome (SS). Ectopic germinal centers (GCs) in the salivary glands are predictors of the occurrence of NHL. Given the association between CCL11 and CXCL13 and ectopic GCs, we assessed the link between these chemokines and NHL, as well as the association between these chemokines and disease activity, in patients with primary SS.Methods: Serum levels of CCL11 and CXCL13 were evaluated by multiplex assay in 385 patients included in the Assessment of Systemic Signs and Evolution of Sjögren's Syndrome (ASSESS) cohort. The association between chemokine levels, B cell biomarkers, and patient subsets was assessed using Spearman's test for continuous data and the nonparametric Mann‐Whitney U test for categorical data. Multivariate analyses were performed to identify parameters associated with lymphoma and disease activity.Results: Seventeen patients had a history of lymphoma, and 5 of them had developed NHL during followup. The median serum levels of CCL11 and CXCL13 in the total cohort were 106.48 pg/ml (interquartile range 69.33–149.85) and 108.31 pg/ml (interquartile range 58.88–200.13), respectively. Patients with lymphoma had higher levels of CXCL13 than did patients without lymphoma (P = 0.006) and a trend toward a higher level of CCL11 (P = 0.056). Low C4 and high BAFF levels were associated with NHL on multivariate analysis (P = 0.01 and P = 0.0002, respectively). CCL11 and CXCL13 levels correlated positively with the rheumatoid factor titer, the κ‐to‐λ free light chain ratio, and the β2‐microglubulin level. CXCL13 was the only parameter associated with disease activity on multivariate analysis.Conclusion: These findings demonstrate a link between CXCL13 and CCL11 and disease activity and lymphoma. This highlights the continuum between chronic B cell activation, disease activity, and lymphomagenesis in patients with primary SS.Keywords
Funding Information
- French Ministry of Health (PHRC 2006-AOM06133)
- French Ministry of Research (ANR- 2010-BLAN-1133 01)
- Pfizer
This publication has 34 references indexed in Scilit:
- Sjögren Syndrome‐associated lymphomas: an update on pathogenesis and managementBritish Journal of Haematology, 2014
- The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2014
- Genetic associations to germinal centre formation in primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2014
- A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphomaBlood, 2013
- Advances in understanding the pathogenesis of primary Sjögren's syndromeNature Reviews Rheumatology, 2013
- Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS CohortPLOS ONE, 2013
- Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2011
- Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndromeArthritis & Rheumatism, 2003
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- Sjöc;gren's Syndrome: Autoimmune EpithelitisClinical Immunology and Immunopathology, 1994